Sera Prognostics (NASDAQ:SERA) Insider Tiffany Eul Davis Inglis Sells 8,024 Shares of Company Stock

Key Points

• Insider sale: Tiffany Eul Davis Inglis sold 8,024 Sera Prognostics shares for approximately $16,289 at an average price of $2.03. The sale covered tax-withholding obligations, reducing her stake by 8.76% to 83,565 shares.
• Weak financial results: Sera Prognostics reported a quarterly loss of $0.18 per share, missing estimates by $0.03, while revenue of $0.03 million fell short of the $0.07 million forecast.
• Stock and analyst outlook: Shares recently traded near $2.04, versus a 52-week range of $1.56 to $3.95. Analysts’ consensus rating is “Moderate Buy,” with a $5.50 price target, though Weiss Ratings downgraded the stock to “sell.”

Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) insider Tiffany Eul Davis Inglis sold 8,024 shares of the business's stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $2.03, for a total value of $16,288.72. Following the completion of the transaction, the insider owned 83,565 shares in the company, valued at $169,636.95. The trade was a 8.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tiffany Eul Davis Inglis also recently made the following trade(s):

• On Thursday, September 10th, Tiffany Eul Davis Inglis sold 486 shares of Sera Prognostics stock. The stock was sold at an average price of $2.00, for a total value of $972.00.

Sera Prognostics Price Performance

Shares of NASDAQ:SERA traded down $0.03 during trading on Tuesday, hitting $2.04. 4,687 shares of the company's stock were exchanged, compared to its average volume of 45,591. Sera Prognostics, Inc. has a 52-week low of $1.56 and a 52-week high of $3.95. The business's 50-day simple moving average is $2.04 and its 200 day simple moving average is $2.02. The company has a market cap of $80.48 million, a price-to-earnings ratio of -3.04 and a beta of 1.06.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.03). Sera Prognostics had a negative return on equity of 46.71% and a negative net margin of 47,475.72%. The business had revenue of $0.03 million during the quarter, compared to analysts' expectations of $0.07 million. On average, sell-side analysts anticipate that Sera Prognostics, Inc. will post -0.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. AWM Investment Company Inc. bought a new stake in shares of Sera Prognostics in the second quarter worth about $377,000. Segall Bryant & Hamill LLC bought a new position in Sera Prognostics during the first quarter valued at approximately $193,000. Finally, Arkadios Wealth Advisors bought a new position in Sera Prognostics during the first quarter valued at approximately $25,000. Institutional investors own 54.64% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Sera Prognostics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $5.50.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a women's health diagnostics company focused on improving pregnancy outcomes through biomarker-based testing. The company develops and commercializes blood tests designed to identify women at elevated risk for pregnancy complications, particularly spontaneous preterm birth.

Its lead product, the PreTRM Test, is a blood-based test that analyzes proteins associated with pregnancy and provides an individualized risk assessment for spontaneous preterm birth in singleton pregnancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.